Myelodysplastic syndromes are characterized as a clonal disorder that is diagnosed by the detection of cytopenias in peripheral blood; They are pathologies that are associated with elderly people and generally have a poor prognosis. Its diagnosis is based on findings in peripheral blood (cytopenia), bone marrow (cellularity and morphology) as well as cytogenetic evaluation. Among the cytopenias studied in patients with Myelodysplastic Syndrome, thrombocytopenia stands out; because this platelet deficiency can lead patients to have bleeding ranging from mild to severe. It has been studied that thrombocytopenia at the time of diagnosis has an adverse effect on the prognosis of patients with MDS, making it a relevant aspect in the course of the disease for patients. In this way, the morphological findings of the platelets together with the platelet indices at the time of diagnosis are an important factor associated with the development of the disease. This is why the possibility is being studied that by measuring platelet values, including reticulated platelets in peripheral blood, and identifying the morphology of these cells in patients diagnosed with myelodysplastic syndrome compared to healthy individuals, important data are generated that can put platelets as a possible biomarker of prognostic value.